Molekulyarnaya Meditsina (Molecular medicine)Molekulyarnaya Meditsina (Molecular medicine)Молекулярная медицина1728-29182499-9490Russkiy Vrach Publishing House67728810.29296/24999490-2024-06-05ReviewsОбзорыReview ArticleUse of nanotechnology in the creation of targeted drugs for the treatment of oncological diseasesИспользование нанотехнологий при создании таргетных препаратов для лечения онкологических заболеванийhttps://orcid.org/0000-0001-5623-4226SeliverstovPavel VasilyevichСеливёрстовПавел Васильевич
Russian Federation

Associate Professor, 2nd Department (Advanced Medical Therapy)

доцент 2-й кафедры (терапии усовершенствования врачей), кандидат медицинских наук, доцент

seliverstov-pv@yandex.ruhttps://orcid.org/0009-0002-0293-5419BaksheevaAnastasia DmitrievnaБакшееваАнастасия Дмитриевна
Russian Federation

6th year student

студентка VI курса

baksheeva.anastasiya@mail.ruhttps://orcid.org/0009-0007-5563-6785KoretskayaPolina SergeevnaКорецкаяПолина Сергеевна
Russian Federation

5th year student

студентка V курса

pollyligman.q@gmail.comhttps://orcid.org/0009-0007-2928-5141AbdusattarovIzattillo Zukhriddin ugliАбдусаттаровИззатило Зухриддин угли
Russian Federation

6th year student

студент VI курса

pollyligman.q@gmail.comFederal State Budgetary Educational Institution of Higher Education “S.M. Kirov Military Medical Academy” of the Ministry of Health of the Russian FederationФГБВОУ ВО «Военно-медицинская академия имени С.М. Кирова» МО РФPeoples' Friendship University of Russia named after Patrice LumumbaФедеральное государственное автономное образовательное учреждение высшего образования «Российский университет дружбы народов имени Патриса Лумумбы»Federal State Autonomous Educational Institution of Higher Education «N.I. Pirogov Russian National Research Medical University» of the Ministry of Health of the Russian FederationФГАОУ ВО РНИМУ им. Н.И. Пирогова Минздрава России (Пироговский Университет)FSBEI HE “Orenburg State Medical University” Ministry of Healthcare of the Russian FederationФедеральное государственное бюджетное образовательное учреждение высшего образования «Оренбургский государственный медицинский университет» Министерства здравоохранения Российской Федерации1512202422640511703202517032025Copyright ©; 2024, Russkiy Vrach Publishing HouseCopyright ©; 2024, ИД "Русский врач"2024Russkiy Vrach Publishing HouseИД "Русский врач"https://journals.eco-vector.com/1728-2918/article/view/677288

Objective. To analyze current advances in nanotechnology applications for the development of targeted drugs in oncology, including their mechanisms of action and clinical application prospects.

Material and methods. A comprehensive analysis of scientific literature on nanotechnology applications in anti-cancer drug development was conducted. PubMed, Scopus, and Web of Science databases were used for the period 2000–2024.

Results. The main types of nanoparticles used in oncology, their physicochemical properties, and tumor delivery mechanisms were systematized. The principles of the EPR effect and strategies for improving targeted drug delivery were described. Modern approaches to nanoparticle modification for enhancing their therapeutic efficacy were analyzed.

Conclusion. Nanotechnology represents a promising direction in the development of anti-cancer drugs, enabling improved therapy efficacy and safety. The use of drug delivery nanosystems helps overcome biological barriers and enhance pharmacokinetic parameters of drugs.

Цель исследования. Анализ современных достижений в области применения нанотехнологий для создания таргетных препаратов в онкологии, включая механизмы их действия и перспективы клинического применения.

Материал и методы. Проведен комплексный анализ научной литературы по применению нанотехнологий в разработке противоопухолевых препаратов. Использованы базы данных PubMed, Scopus и Web of Science за период 2000–2024 гг.

Результаты. Систематизированы основные типы наночастиц, применяемых в онкологии, их физико-химические свойства и механизмы доставки в опухолевую ткань. Описаны принципы EPR-эффекта и стратегии улучшения целевой доставки препаратов. Проанализированы современные подходы к модификации наночастиц для повышения их терапевтической эффективности.

Заключение. Нанотехнологии представляют собой перспективное направление в разработке противоопухолевых препаратов, позволяющее повысить эффективность и безопасность терапии. Применение наносистем доставки лекарств способствует преодолению биологических барьеров и улучшению фармакокинетических параметров препаратов.

nanotechnologytargeted therapyoncologynanoparticlesEPR effectanti-cancer drugsdrug delivery systemsnanomedicineнанотехнологиитаргетная терапияонкологиянаночастицыEPR-эффектпротивоопухолевые препаратысистемы доставки лекарствнаномедицинаZhang Y., Li M., Gao X., Chen Y., Liu T. Nanotechnology in cancer diagnosis: progress, challenges and opportunities. J. Hematol. Oncol. 2019; 12 (1): 137. DOI: 10.1186/s13045-019-0833-3Slamon D., Eiermann W., Robert N., Pienkowski T., Martin M., Press M., Mackey J. et al. Adjuvant trastuzumab in HER2 positive breast cancer. N. Engl. J. Med. 2011; 365 (14): 1273–83. DOI: 10.1056/NEJMoa0910383Druker B.J., Guilhot F., O'Brien S.G., Gathmann I., Kantarjian H., Gattermann N., Deininger M.W. et al. Five year follow up of patients receiving imatinib for chronic myeloid leukemia. N. Engl. J. Med. 2006; 355 (23): 2408–17. DOI: 10.1056/NEJMoa062867Lynch T.J., Bell D.W., Sordella R., Gurubhagavatula S., Okimoto R.A., Brannigan B.W., Harris P.L. et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non small cell lung cancer to gefitinib. N. Engl. J. Med. 2004; 350 (21): 2129–39. DOI: 10.1056/NEJMoa040938Hurwitz H., Fehrenbacher L., Novotny W., Cartwright T., Hainsworth J., Heim W., Berlin J. et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 2004; 350 (23): 2335–42. DOI: 10.1056/NEJMoa032691Ledermann J., Harter P., Gourley C., Friedlander M., Vergote I., Rustin G., Scott C.L. et al. Olaparib maintenance therapy in platinum sensitive relapsed ovarian cancer. N. Engl. J. Med. 2012; 366 (15): 1382–92. DOI: 10.1056/NEJMoa1105535Barenholz Y. Doxil – the first FDA approved nano drug: lessons learned. J. Control. Release. 2012; 160 (2): 117–34. DOI: 10.1016/j.jconrel.2012.03.020Gradishar W.J., Tjulandin S., Davidson N., Shaw H., Desai N., Bhar P., Hawkins M. et al. Phase III trial of nanoparticle albumin bound paclitaxel compared with polyethylated castor oil based paclitaxel in women with breast cancer. J. Clin. Oncol. 2005; 23 (31): 7794–803. DOI: 10.1200/JCO.2005.04.937Michalet X., Pinaud F.F., Bentolila L.A., Tsay J.M., Doose S., Li J.J., Sundaresan G. et al. Quantum dots for live cells, in vivo imaging, and diagnostics. Science. 2005; 307 (5709): 538–44. DOI: 10.1126/science.1104274Petros R.A., DeSimone J.M. Strategies in the design of nanoparticles for therapeutic applications. Nat. Rev. Drug Discov. 2010; 9 (8): 615–27. DOI: 10.1038/nrd2591Jokerst J.V., Lobovkina T., Zare R.N., Gambhir S.S. Nanoparticle PEGylation for imaging and therapy. Nanomedicine (Lond). 2011; 6 (4): 715–28. DOI: 10.2217/nnm.11.19Pankhurst Q.A., Connolly J., Jones S.K., Dobson J. Applications of magnetic nanoparticles in biomedicine. J. Phys. D: Appl. Phys. 2003; 36 (13): R167. DOI: 10.1088/0022-3727/36/13/201Matsumura Y., Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 1986; 46 (12): 6387–92.Hobbs S.K., Monsky W.L., Yuan F., Roberts W.G., Griffith L., Torchilin V.P., Jain R.K. et al. Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. Proc. Natl. Acad. Sci. USA. 1998; 95 (8): 4607–12. DOI: 10.1073/pnas.95.8.4607Maeda H., Wu J., Sawa T., Matsumura Y., Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J. Control. Release. 2000; 65 (1–2): 271–84. DOI: 10.1016/s0168-3659(99)00248-5Jain R.K. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science. 2005; 307 (5706): 58–62. DOI: 10.1126/science.1104819Heldin C.H., Rubin K., Pietras K., Ostman A. High interstitial fluid pressure – an obstacle in cancer therapy. Nat. Rev. Cancer. 2004; 4 (10): 806–13. DOI: 10.1038/nrc1456Ganta S., Devalapally H., Shahiwala A., Amiji M. A review of stimuli responsive nanocarriers for drug and gene delivery. J. Control. Release. 2008; 126 (3): 187–204. DOI: 10.1016/j.jconrel.2007.12.017Heitz F., Morris M.C., Divita G. Twenty years of cell penetrating peptides: from molecular mechanisms to therapeutics. Br. J. Pharmacol. 2009; 157 (2): 195–206. DOI: 10.1111/j.1476-5381.2009.00057.xBangham A.D., Standish M.M., Watkins J.C. Diffusion of univalent ions across the lamellae of swollen phospholipids. J. Mol. Biol. 1965; 13 (1): 238–52. DOI: 10.1016/S0022-2836(65)80093-6Drummond D.C., Zignani M., Leroux J.C. Current status of pH sensitive liposomes in drug delivery. Prog. Lipid Res. 2000; 39 (5): 409–60. DOI: 10.1016/s0163-7827(00)00011-4Gabizon A., Shmeeda H., Barenholz Y. Pharmacokinetics of pegylated liposomal doxorubicin: review of animal and human studies. Clin. Pharmacokinet. 2003; 42 (5): 419–36. DOI: 10.2165/00003088-200342050-00002Wang-Gillam A., Li C.P., Bodoky G., Dean A., Shan Y.S., Jameson G., Macarulla T. et al. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine based therapy (NAPOLI-1): a global, randomised, open label, phase 3 trial. Lancet. 2016; 387 (10018): 545–57. DOI: 10.1016/S0140-6736(15)00986-1Walsh T.J., Finberg R.W., Arndt C., Hiemenz J., Schwartz C., Bodensteiner D., Pappas P. et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. N. Engl. J. Med. 1999; 340 (10): 764–71. DOI: 10.1056/NEJM199903113401004Lancet J.E., Uy G.L., Cortes J.E., Newell L.F., Lin T.L., Ritchie E.K., Stuart R.K. et al. CPX-351 (cytarabine and daunorubicin) liposome for injection versus conventional cytarabine plus daunorubicin in older patients with newly diagnosed secondary acute myeloid leukemia. J. Clin. Oncol. 2018; 36 (26): 2684–92. DOI: 10.1200/JCO.2017.77.6112Kim T.Y., Kim D.W., Chung J.Y., Shin S.G., Kim S.C., Heo D.S., Kim N.K. et al. Phase I and pharmacokinetic study of Genexol-PM, a cremophor free, polymeric micelle formulated paclitaxel, in patients with advanced malignancies. Clin. Cancer Res. 2004; 10 (11): 3708–16. DOI: 10.1158/1078-0432.CCR-03-0655Anderson J.M., Shive M.S. Biodegradation and biocompatibility of PLA and PLGA microspheres. Adv. Drug Deliv. Rev. 2012; 64: 72–82. DOI: 10.1016/j.addr.2012.09.004Davis M.E., Zuckerman J.E., Choi C.H.J., Seligson D., Tolcher A., Alabi C.A., Yen Y. et al. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature. 2010; 464 (7291): 1067–70. DOI: 10.1038/nature08956Boussif O., Lezoualc'h F., Zanta M.A., Mergny M.D., Scherman D., Demeneix B., Behr J.P. A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine. Proc. Natl. Acad. Sci. USA. 1995; 92 (16): 7297–301. DOI: 10.1073/pnas.92.16.7297Pack D.W., Hoffman A.S., Pun S., Stayton P.S. Design and development of polymers for gene delivery. Nat. Rev. Drug Discov. 2005; 4 (7): 581–93. DOI: 10.1038/nrd1775Whitehead K.A., Langer R., Anderson D.G. Knocking down barriers: advances in siRNA delivery. Nat. Rev. Drug Discov. 2009; 8 (2): 129–38. DOI: 10.1038/nrd2742Young C., Schluep T., Hwang J., Martin S. CRLX101 (formerly IT-101) – A Novel Nanopharmaceutical of Camptothecin in Clinical Development. Curr. Bioact. Compd. 2011; 7 (1): 8–14. DOI: 10.2174/157340711795163802Danhier F., Ansorena E., Silva J.M., Coco R., Le Breton A., Préat V. PLGA based nanoparticles: an overview of biomedical applications. J. Control. Release. 2012; 161 (2): 505–22. DOI: 10.1016/j.jconrel.2012.01.043Huang X., Jain P.K., El-Sayed I.H., El-Sayed M.A. Plasmonic photothermal therapy (PPTT) using gold nanoparticles. Lasers Med. Sci. 2008; 23 (3): 217–28. DOI: 10.1007/s10103-007-0470-xToth G.B., Varallyay C.G., Horvath A., Bashir M.R., Choyke P.L., Daldrup-Link H.E., Dosa E. et al. Current and potential imaging applications of ferumoxytol for magnetic resonance imaging. Kidney Int. 2017; 92 (1): 47–66. DOI: 10.1016/j.kint.2016.12.037Maier-Hauff K., Ulrich F., Nestler D., Niehoff H., Wust P., Thiesen B., Orawa H. et al. Efficacy and safety of intratumoral thermotherapy using magnetic iron oxide nanoparticles combined with external beam radiotherapy on patients with recurrent glioblastoma multiforme. J. Neurooncol. 2011; 103 (2): 317–24. DOI: 10.1007/s11060-010-0389-0Khlebtsov N., Dykman L. Biodistribution and toxicity of engineered gold nanoparticles: a review of in vitro and in vivo studies. Chem. Soc. Rev. 2011; 40 (3): 1647–71. DOI: 10.1039/c0cs00018cHodi F.S., O'Day S.J., McDermott D.F., Weber R.W., Sosman J.A., Haanen J.B., Gonzalez R. et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 2010; 363 (8): 711–23. DOI: 10.1056/NEJMoa1003466Kumar A., Zhang X., Liang X.J. Gold nanoparticles: emerging paradigm for targeted drug delivery system. Biotechnol. Adv. 2013; 31 (5): 593–606. DOI: 10.1016/j.biotechadv.2012.10.002Xie J., Lee S., Chen X. Nanoparticle based theranostic agents. Adv. Drug Deliv. Rev. 2010; 62 (11): 1064–79. DOI: 10.1016/j.addr.2010.07.009Bonvalot S., Rutkowski P.L., Thariat J., Carrère S., Ducassou A., Sunyach M.P., Agoston P. et al. NBTXR3, a first in class radioenhancer hafnium oxide nanoparticle, plus radiotherapy versus radiotherapy alone in patients with locally advanced soft tissue sarcoma (Act.In.Sarc): a multicentre, phase 2-3, randomised, controlled trial. Lancet Oncol. 2019; 20 (8): 1148–59. DOI: 10.1016/S1470-2045(19)30326-2Wood B.J., Poon R.T., Locklin J.K., Dreher M.R., Ng K.K., Eugeni M., Seidel G. et al. Phase I study of heat deployed liposomal doxorubicin during radiofrequency ablation for hepatic malignancies. J. Vasc. Interv. Radiol. 2012; 23 (2): 248–55. DOI: 10.1016/j.jvir.2011.10.018Patel N.R., Pattni B.S., Abouzeid A.H., Torchilin V.P. Nanopreparations to overcome multidrug resistance in cancer. Adv. Drug Deliv. Rev. 2013; 65 (13–14): 1748–62. DOI: 10.1016/j.addr.2013.08.004Riley R.S., Day E.S. Gold nanoparticle mediated photothermal therapy: applications and opportunities for multimodal cancer treatment. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 2017; 9 (4): e1449. DOI: 10.1002/wnan.1449Choi Y.E., Kwak J.W., Park J.W. Nanotechnology for early cancer detection. Sensors (Basel). 2010; 10 (1): 428–55. DOI: 10.3390/s100100428Wilhelm S., Tavares A.J., Dai Q., Ohta S., Audet J., Dvorak H.F., Chan W.C.W. Analysis of nanoparticle delivery to tumours. Nat. Rev. Mater. 2016; 1: 16014. DOI: 10.1038/natrevmats.2016.14Ishida T., Kashima S., Kiwada H. The contribution of phagocytic activity of liver macrophages to the accelerated blood clearance (ABC) phenomenon of PEGylated liposomes in rats. J. Control. Release. 2008; 126 (2): 162–5. DOI: 10.1016/j.jconrel.2007.11.009Kreuter J. Drug delivery to the central nervous system by polymeric nanoparticles: what do we know? Adv. Drug Deliv. Rev. 2014; 71: 2–14. DOI: 10.1016/j.addr.2013.08.008Resnik D.B., Tinkle S.S. Ethics in nanomedicine. Nanomedicine (Lond). 2007; 2 (3): 345–50. DOI: 10.2217/17435889.2.3.345Etheridge M.L., Campbell S.A., Erdman A.G., Haynes C.L., Wolf S.M., McCullough J. The big picture on nanomedicine: the state of investigational and approved nanomedicine products. Nanomedicine. 2013; 9 (1): 1–14. DOI: 10.1016/j.nano.2012.05.013